Free tool
FAERS Monitor: Nicoderm Cq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020165 or its brand name (Nicoderm Cq, Nicotine). Reports on generic versions are filed under their own applications.
Reports
32,903
Serious
13,260
40% of reports
Hospitalization
5,702
Death reported
1,800
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,903
- application site erythema3,144
- application site pruritus3,075
- nausea2,627
- nicotine dependence2,147
- dizziness1,674
- headache1,431
- malaise1,406
- application site irritation1,112
- product adhesion issue1,099
- application site pain1,047
- application site rash1,044
- dyspnoea1,044
- insomnia1,038
- vomiting1,029
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 354 |
| 2005 | 3,368 |
| 2006 | 3,412 |
| 2007 | 571 |
| 2008 | 409 |
| 2009 | 526 |
| 2010 | 597 |
| 2011 | 686 |
| 2012 | 723 |
| 2013 | 855 |
| 2014 | 769 |
| 2015 | 2,948 |
| 2016 | 2,246 |
| 2017 | 1,787 |
| 2018 | 2,891 |
| 2019 | 1,974 |
| 2020 | 1,612 |
| 2021 | 1,462 |
| 2022 | 1,173 |
| 2023 | 1,185 |
| 2024 | 1,220 |
| 2025 | 1,257 |
| 2026 | 878 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,021,256 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| nicotine dependenceSignal | 2,147 | 243.3 | 231.7 | 375,104 |
| application site pruritusSignal | 3,075 | 100.0 | 96.5 | 260,902 |
| application site erythemaSignal | 3,144 | 87.0 | 83.9 | 235,423 |
| application site irritationSignal | 1,112 | 62.6 | 58.9 | 61,400 |
| application site rashSignal | 1,044 | 52.4 | 49.3 | 48,661 |
| application site painSignal | 1,047 | 31.8 | 30.0 | 29,801 |
| product adhesion issueSignal | 1,099 | 20.3 | 19.1 | 19,511 |
| insomniaSignal | 1,038 | 2.5 | 2.4 | 938 |
| dizzinessSignal | 1,674 | 2.1 | 2.1 | 1,049 |
| nauseaSignal | 2,627 | 2.1 | 2.0 | 1,620 |
| malaiseSignal | 1,406 | 2.1 | 2.0 | 772 |
| drug ineffective | 3,903 | 1.9 | 1.8 | 1,756 |
| headache | 1,431 | 1.5 | 1.4 | 213 |
| vomiting | 1,029 | 1.4 | 1.3 | 120 |
| dyspnoea | 1,044 | 1.2 | 1.1 | 29 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.